Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Galmed Pharmaceuticals Ltd (GLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GLMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -52.69% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.35M USD | Price to earnings Ratio 0.02 | 1Y Target Price 12 |
Price to earnings Ratio 0.02 | 1Y Target Price 12 | ||
Volume (30-day avg) 1750137 | Beta 0.72 | 52 Weeks Range 1.33 - 15.10 | Updated Date 04/2/2025 |
52 Weeks Range 1.33 - 15.10 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 69.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.98% | Return on Equity (TTM) -37.22% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value -10248072 | Price to Sales(TTM) - |
Enterprise Value -10248072 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.32 | Shares Outstanding 1656990 | Shares Floating 1311297 |
Shares Outstanding 1656990 | Shares Floating 1311297 | ||
Percent Insiders 1.89 | Percent Institutions 3.08 |
Analyst Ratings
Rating 4 | Target Price 4 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Galmed Pharmaceuticals Ltd
Company Overview
History and Background
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases. Founded in 2000, it has primarily focused on Aramchol, its lead product candidate.
Core Business Areas
- Drug Development: Galmed focuses on researching, developing, and commercializing novel therapeutics for liver diseases, with a primary focus on non-alcoholic steatohepatitis (NASH).
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Information on organizational structure would require access to their official records.
Top Products and Market Share
Key Offerings
- Aramchol: Aramchol is Galmed's lead product candidate, a SCD1 modulator for the treatment of NASH and fibrosis. Since the drug has not yet been approved, there is no market share data. Competitors include Madrigal Pharmaceuticals (MDGL) with Rezdiffra, Intercept Pharmaceuticals (ICPT) acquired by Alfasigma.
Market Dynamics
Industry Overview
The NASH market is a large and growing market with significant unmet need. Several companies are developing therapies for NASH and fibrosis.
Positioning
Galmed aims to be a key player in the NASH market by developing and commercializing Aramchol. They are pursuing a niche focus on SCD1 modulation.
Total Addressable Market (TAM)
The NASH market is estimated to be worth billions of dollars annually once effective therapies are approved. Galmed's positioning within this TAM is dependent on the approval and commercial success of Aramchol.
Upturn SWOT Analysis
Strengths
- Focus on a specific mechanism of action (SCD1 modulation)
- Potential for oral administration of Aramchol
- Experienced management team
Weaknesses
- Single product pipeline (Aramchol)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on regulatory approval
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of Aramchol into other liver disease indications
- Advancements in diagnostic technologies for NASH
Threats
- Failure to obtain regulatory approval for Aramchol
- Competition from other NASH therapies
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- MDGL
- ICPT
Competitive Landscape
Galmed faces significant competition from larger pharmaceutical companies with more resources. Their strength lies in their specific mechanism of action and oral administration. The NASH market is still developing, with no clear leader in terms of market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Galmed's historical growth has been characterized by progress in clinical trials and regulatory submissions.
Future Projections: Future growth is dependent on the successful development and commercialization of Aramchol. Analyst estimates can vary depending on clinical trial outcomes and regulatory decisions.
Recent Initiatives: Recent initiatives include advancing Aramchol through clinical trials and seeking potential partnerships.
Summary
Galmed Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on NASH. Its success hinges on Aramchol's clinical trial outcomes and regulatory approval. The company's small size presents both opportunities and challenges, requiring strategic partnerships and efficient capital management. Investment carries substantial risk given the regulatory landscape and competition in the NASH space.
Similar Companies
MDGL
Madrigal Pharmaceuticals Inc
MDGL
Madrigal Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in pharmaceutical companies involves significant risk. Market share data represents potential market share once a drug is approved.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galmed Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-13 | Co-Founder, President, CEO & Chairman Mr. Allen Baharaff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.galmedpharma.com |
Full time employees 3 | Website https://www.galmedpharma.com | ||
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.